Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression.

@article{Dean2014DesignAR,
  title={Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression.},
  author={Olivia M Dean and Alyna Turner and Gin S. Malhi and Chee H Ng and Sue M Cotton and Seetal Dodd and Jerome Sarris and Yuval Samuni and Michelle Tanious and Nathan Dowling and Astrid Waterdrinker and Deidre J Smith and Michael Berk},
  journal={Revista brasileira de psiquiatria},
  year={2014},
  volume={37 1},
  pages={
          3-12
        }
}
OBJECTIVE Bipolar disorder places a significant burden on individuals, caregivers and family, and the broader community. Current treatments are believed to be more effective against manic symptoms, leaving a shortfall in recovery during the depressive phase of the illness. The current study draws on recent evidence suggesting that, in addition to increased oxidative load, alterations in mitochondrial function occur in bipolar disorder. METHODS This 16-week study aims to explore the potential… CONTINUE READING

Tables and Topics from this paper.

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

Mitochondrial Agents for Bipolar Disorder

  • The international journal of neuropsychopharmacology
  • 2018
VIEW 4 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 78 REFERENCES

acetylcysteine in neuropsychiatry

PF Chinnery, K Majamaa, DM Turnbull, D. Thornburn
  • Trends Pharmacol Sci
  • 2013